Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Abstract Text:

Reinhard H A Becker,Annke D Frick,Reinhard H A Becker,Annke D Frick,

Insulin glulisine injection [3(B)-Lys, 29(B)-Glu-human insulin] is the newest human insulin analogue product for the control of mealtime blood sugar. As with insulin aspart and insulin lispro products, the insulin glulisine product displays faster absorption and onset of action, with a shorter duration of action than that of regular human insulin.The modifications of the amino acid sequence at positions 3 and 29 in the B chain of human insulin simultaneously provide stability to the molecular structure and render the insulin glulisine molecule less likely to self-associate, compared with human insulin, while still allowing the formation of dimers at pharmaceutical concentrations. Unlike other insulin analogue products, this allows for a viable drug product in the absence of hexamer-promoting zinc and, thus, provides immediate availability of insulin glulisine molecules at the injection site for absorption.Pharmacokinetic studies with insulin glulisine have shown an absorption profile with a peak insulin concentration approximately twice that of regular human insulin, which is reached in approximately half the time. Dose proportionality in early, maximum and total exposure is observed for insulin glulisine over the therapeutic relevant dose range up to 0.4 U/kg.The pharmacodynamic profile of insulin glulisine reflects the absorption kinetics by demonstrating a greater rate of glucose utilization, which is completed earlier and at equipotency on a molar base compared with regular human insulin. Dose-proportionality in glucose utilization has been established for insulin glulisine in patients with type 1 diabetes mellitus in the dose range of 0.075-0.15 U/kg, and a less than dose-proportional increase above 0.15 U/kg, indicating saturation of insulin action in general.The rapid absorption and action of insulin glulisine show similar low intrasubject variability compared with insulin lispro and regular human insulin when given repeatedly, and have been confirmed in healthy subjects of different body mass indices (BMIs) and ethnic groups, as well as adults and children with type 1 and type 2 diabetes. Furthermore, the early insulin exposure and action of insulin glulisine were slightly - but consistently - greater than those of insulin lispro in healthy volunteers across a wide range of BMIs.Meal studies in patients with type 1 diabetes show that insulin glulisine provides better postprandial blood glucose control than regular human insulin when administered immediately pre-meal, and equivalent control when given after the meal. In a study in patients with type 2 diabetes, the overall postprandial blood glucose excursions were lower with insulin glulisine than with insulin lispro.Therefore, by virtue of its primary structure, insulin glulisine demonstrates both low self-association in solution and stability for a viable insulin product in the absence of zinc, thereby maintaining immediate availability for absorption after subcutaneous injection. This confers the most rapid onset of glucose-lowering activity and adds to the flexibility in postprandial blood glucose control.

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Publishing Authors By Initials

RH Becker,AD Frick,RH Becker,AD Frick,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical pharmacokinetics

VOLUME: 47

Page Numbers: 7-20

Journal Abbreviation:

ISSN: 0312-5963

DAY: 13

MONTH: 12

YEAR: 2008

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7606849

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

AFFILIATION: sanofi-aventis, Frankfurt/Main, Germany.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Pharmacokinet

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Clinical pharmacokinetics and pharmacodynamics of insulin glulisine Related Publications

• Age-dependent effects of environmental enrichment on spatial reference memory in male mice.
• Assessment of health state utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study.
• Association of (c)AMP-Degrading Glycosylphosphatidylinositol-Anchored Proteins with Lipid Droplets Is Induced by Palmitate, H(2)O(2) and the Sulfonylurea Drug, Glimepiride, in Rat Adipocytes.
• Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.
• Cost-effectiveness studies of behavior change communication campaigns: assessing the state of the science and how to move the field forward.
• Effects of estrogen and progesterone on spatial memory consolidation in aged females.
• Exploring the cognitive and emotional correlates to proactive and reactive aggression in a sample of detained girls.
• Gender bias in economic evaluation methods time costs and productivity loss.
• IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells.
• Inhibition of lipolysis by palmitate, h(2)o(2) and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets.
• Life-long environmental enrichment differentially affects the mnemonic response to estrogen in young, middle-aged, and aged female mice.
• Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study.
• Methyl group dynamics in a confined glass.
• Patient characteristics and end-of-life health care utilization among Medicare beneficiaries in 1989 and 1999.
• Protein FOG is a moderate inducer of MIG/CXCL9, and group G streptococci are more tolerant than group A streptococci to this chemokine's antibacterial effect.
• Quasielastic neutron scattering of poly(methyl phenyl siloxane) in the bulk and under severe confinement.
• Race and ethnic disparities in valuing health.
• Single enrichment variables differentially reduce age-related memory decline in female mice.
• SufA a novel subtilisin-like serine proteinase of Finegoldia magna.
• Synthesis of novel anilinoquinolines as c-fms inhibitors.
• The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target.
• [Behavior of heparinocytes and of fibrinolytic degradation products after discontinuation of hormonal contraceptives]
• [Changes in the ureter in radiotherapy of cervical cancer]
• [Demonstration of fibrinolytic split products during administration of hormonal contraceptives]
• [Effects of ethinyloestradiol sulphonate in soft-gelatin capsules on coagulation parameters of weaning women (author's transl)]
• [Hormonal contraception--throboembolism and surgical risk]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Psychotherapy in cancer patients]